文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

针对 SARS-CoV-2 感染的强大中和抗体可长期存在。

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.

机构信息

Department of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

出版信息

Science. 2020 Dec 4;370(6521):1227-1230. doi: 10.1126/science.abd7728. Epub 2020 Oct 28.


DOI:10.1126/science.abd7728
PMID:33115920
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7810037/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)已造成全球性大流行,感染人数达数百万,死亡人数超过 100 万。目前仍不清楚针对该病毒的抗体反应的稳健性、功能性和持久性如何。在此,我们基于纽约市西奈山卫生系统对 30082 个人的筛查数据集报告称,绝大多数患有轻度至中度 COVID-19 的感染者对病毒刺突蛋白产生强烈的免疫球蛋白 G 抗体反应。我们还表明,至少在大约 5 个月的时间内,滴度相对稳定,并且抗刺突结合滴度与真实 SARS-CoV-2 的中和显著相关。我们的数据表明,超过 90%的血清转化者产生可检测的中和抗体反应。这些滴度在感染后几个月内仍相对稳定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d0/7810037/46d94944a70d/370_1227_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d0/7810037/899c291be693/370_1227_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d0/7810037/8ed8c5ba55e3/370_1227_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d0/7810037/46d94944a70d/370_1227_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d0/7810037/899c291be693/370_1227_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d0/7810037/8ed8c5ba55e3/370_1227_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38d0/7810037/46d94944a70d/370_1227_F3.jpg

相似文献

[1]
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.

Science. 2020-10-28

[2]
Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.

J Immunol Methods. 2021-2

[3]
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).

Pediatrics. 2020-9-2

[4]
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.

Viruses. 2021-4-16

[5]
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.

Virol J. 2021-1-12

[6]
Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.

PLoS One. 2022

[7]
An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.

Microbiol Spectr. 2021-10-31

[8]
Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.

Viruses. 2021-10-5

[9]
Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.

J Med Virol. 2021-7

[10]
Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies.

Viruses. 2021-5-18

引用本文的文献

[1]
Circulating SARS-CoV-2 spike IgG antibody responses in cancer patients following multiple COVID-19 vaccination boosters.

Front Immunol. 2025-8-12

[2]
Kinetics of anti-SARS-CoV-2 antibodies and hematological parameters in hospitalized pre-vaccination COVID-19 patients in Peru.

PeerJ. 2025-8-22

[3]
Antibody repertoire associated with clinically diverse presentations of pediatric SARS-CoV-2 infection.

medRxiv. 2025-7-23

[4]
Convalescent plasma therapy and long-term SARS-COV-2 antiviral immune response in a prospective cohort of patients with COVID-19.

Curr Res Microb Sci. 2025-7-9

[5]
The Anti-Nucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection for Hemodialysis Patients.

Vaccines (Basel). 2025-7-13

[6]
Modular DNA barcoding of nanobodies enables multiplexed in situ protein imaging and high-throughput biomolecule detection.

Elife. 2025-7-22

[7]
Sustained natural immunity following SARS-CoV-2 infection against severe COVID-19 outcomes and symptomatic reinfection: analyses of national data for Brazil and Scotland.

BMJ Open. 2025-7-16

[8]
A longitudinal assessment of the antibody response to SARS-CoV-2 infection in the New Mexican population.

PLoS One. 2025-7-8

[9]
Protective Potential and Functional Role of Antibodies Against SARS-CoV-2 Nucleocapsid Protein.

Antibodies (Basel). 2025-5-28

[10]
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection.

Commun Med (Lond). 2025-6-20

本文引用的文献

[1]
Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study.

Lancet Microbe. 2020-11

[2]
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.

Nat Commun. 2020-9-17

[3]
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.

Nat Med. 2020-9-15

[4]
High neutralizing antibody titer in intensive care unit patients with COVID-19.

Emerg Microbes Infect. 2020-12

[5]
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.

Science. 2020-7-2

[6]
An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.

Curr Protoc Microbiol. 2020-9

[7]
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development.

Proc Natl Acad Sci U S A. 2020-6-22

[8]
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.

Nat Med. 2020-6-18

[9]
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.

Nature. 2020-5-26

[10]
SARS-CoV-2 infection protects against rechallenge in rhesus macaques.

Science. 2020-5-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索